August 17, 2021
Wall Street Journal "Follow Your Nose to Herd Immunity"
August 8, 2021
British Medical Journal Transparency in covid vaccine research
June 11, 2021
Heart disease possibly related to the Pfizer Vaccine: detailed UK report
May 12, 2021
May 12, 2021
CDC data in a piece by Larry Solomon
May 11, 2021
April 20, 2021
The Lancet: Covid vaccine efficacy and effectiveness: The elephant (not) in the room
Vaccine efficacy is generally reported as a relative risk reduction (RRR). It uses the relative risk (RR)—ie, the ratio of attack rates with and without a vaccine—which is expressed as 1–RR. Ranking by reported efficacy gives relative risk reductions of 95% for the Pfizer–BioNTech, 94% for the Moderna–NIH, 90% for the Gamaleya, 67% for the J&J, and 67% for the AstraZeneca–Oxford vaccines. However, RRR should be seen against the background risk of being infected and becoming ill with COVID-19, which varies between populations and over time. Although the RRR considers only participants who could benefit from the vaccine, the absolute risk reduction (ARR), which is the difference between attack rates with and without a vaccine, considers the whole population. ARRs tend to be ignored because they give a much less impressive effect size than RRRs: 1·3% for the AstraZeneca–Oxford, 1·2% for the Moderna–NIH, 1·2% for the J&J, 0·93% for the Gamaleya, and 0·84% for the Pfizer–BioNTech vaccines.
April 19, 2021
TORONTO — Today, Dr. David Williams, Ontario's Chief Medical Officer of Health, issued the following statement to expand COVID-19 vaccination eligibility at pharmacies and primary care settings to individuals aged 40 and over. link